Research findings from the Johns Hopkins Kimmel Cancer Center show how higher viscosity, or resistance to flow, of the extracellular fluid that surrounds cells enables cancer cells to migrate more rapidly from a primary tumor to other sites in the body.
People with operable non-small cell lung cancers may fare better over the next few years by receiving immunotherapy treatments before and after surgery instead of only before surgery, according to an analysis by Johns Hopkins Kimmel Cancer Center investigators.
